Back to results

Allopurinol Maintenance Study for Bipolar Disorder

Primary Purpose

Bipolar Disorder, Mania, Mixed Mania

Status

Terminated

Phase

Phase 4

Locations

United States

Study Type

Interventional

Intervention

Allopurinol

About this trial

This is an interventional prevention trial for Bipolar Disorder focused on measuring Bipolar Disorder, Stable Bipolar Disorder, Mania, Mixed mania, Allopurinol

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects must be between ages 18 and 70.
Subjects must meet diagnostic and statistical manual of mental disorders 4th edition criteria for bipolar disorder confirmed by the Mini International Neuropsychiatric Interview.
Subjects must be taking at least one medication for mania at a therapeutic dose for at least 2 weeks.
Subjects must have been diagnosed with bipolar disorder, type 1, for at least 2 years prior to baseline.
Subjects must have adequate response to medications as evidenced by Young Mania Rating Scale score less than or equal to 10 at screening and at baseline.
Subjects must have adequate response to medications as evidenced by Hamilton Depression Rating Scale score less than or equal to 10 at screening and at baseline.
Subjects must have had at least 1 manic episode in the 2 year period prior to entering the study.
Female subjects must be either postmenopausal for at least 1 year, surgically sterile, abstinent or practicing an effective method of birth control if sexually active. Acceptable methods of birth control during this study are regular use of contraceptive pills, intra-uterine devices, barrier methods or abstinence. Female subjects must also have a negative urine pregnancy test at screening, baseline and other time points throughout the study.
Subjects must be able and willing to comply with self-administration of medication or have consistent help/support available.
Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
Subjects must be able and willing to meet or perform study requirements (e.g. answer self-administered questionnaires).
Subjects must be willing to allow study staff to contact subject's regular psychiatrist while the subject is in the study.

Exclusion Criteria:

Subjects who are unable to provide informed consent.
Subjects with a serious, unstable medical illness (such as cardiovascular, respiratory, neurologic, hematologic, renal, hepatic, endocrine, immunologic, or other systemic illness), a history of cerebrovascular disease, uncontrolled diabetes mellitus or acquired immunodeficiency syndrome (AIDS). Subjects with chronic illness must be stable and otherwise physically healthy on the basis of a physical examination, medical history, electrocardiogram and the results of blood biochemistry, hematology tests and a urinalysis.
Subjects who develop a medical condition during participation which can affect mood stability (i.e. seizure disorder, brain tumors, brain trauma, stroke, multiple sclerosis, etc.)
Subjects who develop substance abuse or dependence during participation in the study.
Subjects taking azathioprine, mercaptopurine, apalcillin, and/or amoxicillin.
Subjects who have been intoxicated with alcohol or drugs within the last 72hrs.
Subjects with a history of severe pre-existing gastrointestinal narrowing or inability to swallow oral study medication whole with the aid of water.
Female subjects who are pregnant or nursing.
Subjects who have previously participated in this study.
Subjects with an anticipated life expectancy of 6 months or less.
Subjects who have received an experimental drug or used an experimental medical device within 1 month of screening.

Sites / Locations

Cedars-Sinai Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Allopurinol

Arm Description

Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.

Outcomes

Primary Outcome Measures

Number of Manic Episodes According to the Young Mania Rating Scale

Young Mania Rating Scale is an 11-item, clinician-administered scale to assess severity of manic symptoms before, during and after treatment. Four items are graded on a min. 0 to max. 8 scale (irritability, speech, thought content and disruptive/aggressive behavior) while the remaining 7 items are graded on a min. 0 to max. 4 scale. A score of 0 indicates behavior is absent and score of 4 or 8 indicates the behavior is present and severe. The change in score between Baseline and the Completion Visit will be reported. Ideally, the two time points will be Baseline and 6 Weeks after Baseline, but if a subject terminates early, the last Young Mania Rating Scale score will be used. The scores from each question are added for a total score ranging from min. 0 to max 60; higher scores indicate greater severity of symptoms. A score of 0-12 indicates the absence of mania or a very mild manic state, a score of 13-20 or higher indicates a mild manic episode, and over 20 indicates a manic state.

Secondary Outcome Measures

Number of Depressive Episodes Per Patient Visit According to the Hamilton Depression Scale

The Hamilton Depression Rating Scale is a tool used to determine a patient's level of depression before, during, and after treatment. The Hamilton Depression Scale form lists 21 items, but the scoring is based on the first 17 questions. Eight items are scored on a 5-point scale, ranging from 0 (min) = not present to 4 (max) = severe. Nine are scored from 0 (min) to 2 (max). The sum of the scores from the first 17 questions is: 0 (min) to 7 (max) = normal, 8 (min) to 13 (max) = mild depression, 14 (min) to 18 (max) = moderate depression, 19 (min) to 22 (max) = severe depression and ≥ 23=very severe depression. A score of 11 or more indicates a depressive episode in terms of this outcome measure.

Number of Psychiatric Hospitalizations

The number of psychiatric hospitalizations that occur during the study will be compared to the number of hospitalizations that occurred prior to the study.

Full Information

NCT ID

NCT00732251

First Posted

August 7, 2008

Last Updated

October 1, 2019

Sponsor

Cedars-Sinai Medical Center

Collaborators

West Coast College of Biological Psychiatry Inc

1. Study Identification

Unique Protocol Identification Number

NCT00732251

Brief Title

Allopurinol Maintenance Study for Bipolar Disorder

Official Title

An Open Label, Naturalistic Study With Allopurinol Augmentation for Prevention of Mania in Bipolar Disorder

Study Type

Interventional

2. Study Status

Record Verification Date

October 2019

Overall Recruitment Status

Terminated

Why Stopped

The outpatient area of the department of psychiatry at CSMC closed.

Study Start Date

August 2008 (undefined)

Primary Completion Date

January 2012 (Actual)

Study Completion Date

January 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Cedars-Sinai Medical Center

Collaborators

West Coast College of Biological Psychiatry Inc

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood.

Detailed Description

The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood. Bipolar disorder is a mental disorder with severe mood swings (mania and depression). Despite the development of medications for mania, they may have significant side effects, high costs and the need for serum level monitoring. These factors adversely affect medication compliance in bipolar patients. One recent study indicated the efficacy of allopurinol in the treatment of bipolar mania. Our hypothesis is that the addition of allopurinol to standard medications for bipolar disorder will decrease the recurrences of manic episodes compared to standard medications. This study will recruit bipolar disorder patients currently mood stable on a therapeutic dose of an anti-manic medication. Stable mood will be defined as a Young Mania Rating Scale score ≤10 and Hamilton Depression Rating Scale ≤10. Subjects must have a diagnosis of bipolar disorder confirmed by the Mini International Neuropsychiatric Interview. Young Mania Rating Scale and Mini International Neuropsychiatric Interview are common research questionnaires used in bipolar disorder studies. Potential subjects will be identified and approached during an outpatient clinical visit by a member of the research team and identified by their treating physicians and referred to the researchers. This study involves adding allopurinol to subjects' current bipolar medications. This study will be a open label, naturalistic study. The subject will be examined monthly for manic symptoms for 2 years. Semi-structured interviews and study questionnaires will be administered to subjects at each visit. Monthly Follow-up Study Visits (once per month for 2 years - Months 1-5, 7-11, 13-17, 19-23) may be conducted either in-person or over the phone. All of the questionnaires will be administered by a clinician if the visit is completed over the phone. However, the 6-month interval visits (Months 6, 12, 18, and 24) must be done at the research center. The primary outcome measure will be the number of manic episodes in the 2 year study period. A manic episode will be defined by a Young Mania Rating Scale score ≥20.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Bipolar Disorder, Mania, Mixed Mania

Keywords

Bipolar Disorder, Stable Bipolar Disorder, Mania, Mixed mania, Allopurinol

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 4

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

15 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Allopurinol

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Allopurinol

Other Intervention Name(s)

Zyloprim, Aloprim

Intervention Description

Allopurinol: 300-600 mg/day over a 24 month period

Primary Outcome Measure Information:

Title

Number of Manic Episodes According to the Young Mania Rating Scale

Description

Time Frame

2 Years

Secondary Outcome Measure Information:

Title

Number of Depressive Episodes Per Patient Visit According to the Hamilton Depression Scale

Description

Time Frame

2 years

Title

Number of Psychiatric Hospitalizations

Description

The number of psychiatric hospitalizations that occur during the study will be compared to the number of hospitalizations that occurred prior to the study.

Time Frame

2 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

70 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Subjects must be between ages 18 and 70. Subjects must meet diagnostic and statistical manual of mental disorders 4th edition criteria for bipolar disorder confirmed by the Mini International Neuropsychiatric Interview. Subjects must be taking at least one medication for mania at a therapeutic dose for at least 2 weeks. Subjects must have been diagnosed with bipolar disorder, type 1, for at least 2 years prior to baseline. Subjects must have adequate response to medications as evidenced by Young Mania Rating Scale score less than or equal to 10 at screening and at baseline. Subjects must have adequate response to medications as evidenced by Hamilton Depression Rating Scale score less than or equal to 10 at screening and at baseline. Subjects must have had at least 1 manic episode in the 2 year period prior to entering the study. Female subjects must be either postmenopausal for at least 1 year, surgically sterile, abstinent or practicing an effective method of birth control if sexually active. Acceptable methods of birth control during this study are regular use of contraceptive pills, intra-uterine devices, barrier methods or abstinence. Female subjects must also have a negative urine pregnancy test at screening, baseline and other time points throughout the study. Subjects must be able and willing to comply with self-administration of medication or have consistent help/support available. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Subjects must be able and willing to meet or perform study requirements (e.g. answer self-administered questionnaires). Subjects must be willing to allow study staff to contact subject's regular psychiatrist while the subject is in the study. Exclusion Criteria: Subjects who are unable to provide informed consent. Subjects with a serious, unstable medical illness (such as cardiovascular, respiratory, neurologic, hematologic, renal, hepatic, endocrine, immunologic, or other systemic illness), a history of cerebrovascular disease, uncontrolled diabetes mellitus or acquired immunodeficiency syndrome (AIDS). Subjects with chronic illness must be stable and otherwise physically healthy on the basis of a physical examination, medical history, electrocardiogram and the results of blood biochemistry, hematology tests and a urinalysis. Subjects who develop a medical condition during participation which can affect mood stability (i.e. seizure disorder, brain tumors, brain trauma, stroke, multiple sclerosis, etc.) Subjects who develop substance abuse or dependence during participation in the study. Subjects taking azathioprine, mercaptopurine, apalcillin, and/or amoxicillin. Subjects who have been intoxicated with alcohol or drugs within the last 72hrs. Subjects with a history of severe pre-existing gastrointestinal narrowing or inability to swallow oral study medication whole with the aid of water. Female subjects who are pregnant or nursing. Subjects who have previously participated in this study. Subjects with an anticipated life expectancy of 6 months or less. Subjects who have received an experimental drug or used an experimental medical device within 1 month of screening.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Itai Danovitch, MD

Organizational Affiliation

Cedars-Sinai Medical Center

Official's Role

Study Chair

Facility Information:

Facility Name

Cedars-Sinai Medical Center

City

Los Angeles

State/Province

California

ZIP/Postal Code

90048

Country

United States

12. IPD Sharing Statement

Links:

URL

http://www.csmc.edu

Description

Cedars-Sinai Medical Center Website

Learn more about this trial

Allopurinol Maintenance Study for Bipolar Disorder

We'll reach out to this number within 24 hrs